Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 1/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.35 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | MARK4 | Q96L34 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL499618 | 1.00 | AOC3 (0.42) | AOC3RIPK1CYP2B6SLC6A2SLC6A4 | |
| SCHEMBL3336584 | 0.82 | AOC3 (0.45) | AOC3SLC6A2SLC6A4TSHRRECQL | |
| SCHEMBL4822741 | 0.82 | AOC3 (0.45) | AOC3SLC6A2SLC6A4TSHRRECQL | |
| SCHEMBL3337325 | 0.82 | AOC3 (0.45) | AOC3SLC6A2SLC6A4TSHRRECQL | |
| SCHEMBL3336585 | 0.82 | AOC3 (0.45) | AOC3SLC6A2SLC6A4TSHRRECQL | |
| SCHEMBL21804705 | 0.82 | MEN1 (0.48) | AOC3RIPK1SLC6A2SLC6A4AURKA | |
| SCHEMBL21804702 | 0.82 | MEN1 (0.48) | AOC3RIPK1SLC6A2SLC6A4AURKA | |
| SCHEMBL21807150 | 0.80 | AOC3 (0.41) | AOC3RIPK1SLC6A2SLC6A4AURKA | |
| SCHEMBL499535 | 0.80 | RIPK1 (0.38) | AOC3RIPK1SLC6A2SLC6A4 | |
| SCHEMBL10254243 | 0.79 | ADRB3 (0.38) | AOC3RIPK1CYP2B6SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106221-B2 | Renin inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-8106221-B2 | Renin inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-20100144825-A1 | Renin Inhibitors | VITAE PHARMACEUTICALS, INC. | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144825-A1 | Renin Inhibitors | ACE, REN, DNPEP | AOC3 2000/4885RIPK1 2175/4885CYP2B6 2984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.